|Alternative Name:||CD178, CD95L, APO-1L, TNFSF 6|
|Immunogen:||Recombinant human FasL (CD95L; APO-1L; CD178) (extracellular domain).|
|Applications:||Flow Cytometry, IHC (FS), IHC (PS), FUNC|
|Recommended Dilutions/Conditions:||Suggested starting dilution is 1:100|
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
|Application Notes:||Excellent for Flow Cytometry.|
Functional Application: neutralizing.
|Purity Detail:||Affinity purified.|
|Formulation:||Liquid. In 0.15M PBS, pH 7.2 containing 1% BSA. Contains no preservatives.|
|Use/Stability:||Stable for at least 6 months when stored at +4°C.|
|Handling:||Keep sterile. Avoid freeze/thaw cycles.|
|Shipping:||Shipped on Blue Ice|
|Long Term Storage:||+4°C|
Figure: Schematic structure of recombinant human FasL (extracellular domain).
: Flow cytometric detection of FasL expression in stimulated H9 T-cells.Method
: H9 T-cells (1x106
) were either left untreated (open histogram) or stimulated with 10ng/ml PMA (Prod. No. ALX-445-004
) and 1µg/ml ionomycin (Prod. No. ALX-450-007
) (filled histogram). After 12 hours cells were harvested and stained with anti-FasL 5G51 (1µg/ml), followed by biotinylated goat anti-mouse IgG and streptavidin-PE.
Figure: Inhibition of apoptosis in anti-CD3 stimulated Jurkat T-cells by anti-Fas L.Method: Jurkat JR cells (2x106) were stimulated with plate-bound anti-CD3 antibodies (10µg/ml) in the presence or absence of the indicated concentrations of anti-FasL 5G51 or a control IgG1 mouse monoclonal antibody. After 48 hours apoptosis was evaluated by flow cytometric analysis of PI-stained nuclei.
Anti-FasL MAb (Prod. No. ALX-804-231
) on HEK 293 wt. and HEK 293-FasL clone cells expressing FasL fusion protein. HEK 293 cells transfected with membrane bound FasL (right figure) were compared with HEK 293 untransfected control cells (left figure).
Please mouse over
Product Literature References
IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway
: M. Schmidt et al.; Eur. J. Immunol. 30
, 1769 (2000), Abstract